Back to results
US 2012/0071470 A1Published application
Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
OwnerDavid Louis Feldman, Randy Lee Webbinventors
Life of this patent
Estimating the term…
Abstract
The invention relates to a pharmaceutical composition comprising (i) a renin inhibitor, (ii) a calcium channel blocker (CCB), and a diuretic and to a method of using such composition for the treatment of cardiovascular disease.
Claims14
1-2. (canceled)
A pharmaceutical composition consisting of
- (i) 1-300 mg aliskiren or a pharmaceutically acceptable salt thereof;
- (ii) 1.0-10 mg amlodipine or a pharmaceutically acceptable salt thereof;
- and
- (iii) 5-25 mg hydrochlorothiazide
- and one or more pharmaceutically acceptable carriers, wherein the amounts of
- (i) aliskiren or a pharmaceutically acceptable salt thereof;
- (ii) amlodipine or a pharmaceutically acceptable salt thereof;
- and
- (iii) hydrochlorothiazide
- administered in combination achieve a greater therapeutic effect than the therapeutic effects achievable with the amounts of
- (i) aliskiren or a pharmaceutically acceptable salt thereof;
- (ii) amlodipine or a pharmaceutically acceptable salt thereof;
- and
- (iii) hydrochlorothiazide
- administered alone.
12 more elements
The pharmaceutical composition of claim 1, consisting of
- (i) 75-225 mg aliskiren or a pharmaceutically acceptable salt thereof;
- (ii) 2.5-7.5 mg amlodipine or a pharmaceutically acceptable salt thereof;
- and
- (iii) 6.0-18 mg hydrochlorothiazide
- and one or more pharmaceutically acceptable carriers.
2 more elements
The pharmaceutical composition of claim 2, consisting of
- (i) 125-175 mg aliskiren or a pharmaceutically acceptable salt thereof;
- (ii) 4.0-6.0 mg amlodipine or a pharmaceutically acceptable salt thereof;
- and
- (iii) 10.5-14.4 mg hydrochlorothiazide
- and one or more pharmaceutically acceptable carriers.
2 more elements
A pharmaceutical composition consisting of
- (i) 1-600 mg aliskiren or a pharmaceutically acceptable salt thereof;
- (ii) 1.0-20 mg amlodipine or a pharmaceutically acceptable salt thereof;
- and
- (iii) 5-50 mg hydrochlorothiazide
- and one or more pharmaceutically acceptable carriers, wherein the amounts of
- (i) aliskiren or a pharmaceutically acceptable salt thereof;
- (ii) amlodipine or a pharmaceutically acceptable salt thereof;
- and
- (iii) hydrochlorothiazide
- administered in combination achieve a greater therapeutic effect than the therapeutic effects achievable with the amounts of
- (i) aliskiren or a pharmaceutically acceptable salt thereof;
- (ii) amlodipine or a pharmaceutically acceptable salt thereof;
- and
- (iii) hydrochlorothiazide
- administered alone.
12 more elements
A method of lowering blood pressure in a hypertensive mammal by administering a pharmaceutical composition consisting of
- (i) 1-300 mg aliskiren or a pharmaceutically acceptable salt thereof;
- (ii) 1.0-10 mg amlodipine or a pharmaceutically acceptable salt thereof;
- and
- (iii) 5-25 mg hydrochlorothiazide
- and one or more pharmaceutically acceptable carriers, wherein the amounts of
- (i) aliskiren or a pharmaceutically acceptable salt thereof;
- (ii) amlodipine or a pharmaceutically acceptable salt thereof;
- and
- (iii) hydrochlorothiazide
- administered in combination achieve a greater therapeutic effect than the therapeutic effects achievable with the amounts of
- (i) aliskiren or a pharmaceutically acceptable salt thereof;
- (ii) amlodipine or a pharmaceutically acceptable salt thereof;
- and
- (iii) hydrochlorothiazide
- administered alone.
12 more elements
Dependencies are inferred from the claim text.